Injosetron

Palonosetron, the active ingredient in Injosetron, is a 5‑HT3 receptor antagonist presented as an intravenous solution for intravenous use. It is indicated for the prevention of both acute and delayed phases of chemotherapy‑induced nausea and vomiting, as well as postoperative nausea and vomiting, in adult patients undergoing cancer treatment or surgery.

GNH USA supplies Injosetron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant facilities and pharmacies worldwide, ensuring quality‑controlled shipments, regulatory compliance and reliable cold‑chain logistics.

Injosetron (palonosetron) acts on the serotonin 5‑HT3 receptor pathway to prevent nausea and vomiting. - Chemotherapy‑induced nausea and vomiting: prevents both acute and delayed nausea and vomiting associated with cytotoxic chemotherapy. - Postoperative nausea and vomiting: reduces incidence of nausea and vomiting after surgical procedures. - Delayed nausea and vomiting: provides control of nausea and vomiting occurring more than 24 hours after chemotherapy administration.

Injosetron may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate headache reported. - Constipation: reduced bowel movements or difficulty passing stool. - Fatigue: feeling of tiredness or lack of energy. - Injection site reactions: erythema, pain or swelling at the IV site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with rash, swelling, airway compromise. - QT interval prolongation: cardiac electrical disturbance that may lead to arrhythmia. - Serotonin syndrome: rare condition with agitation, hyperthermia, tremor when combined with other serotonergic agents.

When using Injosetron, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: assess renal function and monitor for accumulation. - Hepatic impairment: use with caution in patients with liver dysfunction. - Cardiac disease: monitor ECG for QT prolongation, especially in patients with known cardiac risk. - Concomitant serotonergic drugs: evaluate risk of serotonin syndrome when combined with SSRIs, SNRIs or tramadol. - Pregnancy and lactation: prescribe only if potential benefit justifies potential risk to fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Injosetron can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: concurrent use may increase risk of additive cardiac effects. - Cisapride: combined use can markedly prolong QT interval. - Domperidone: may increase risk of ventricular arrhythmias.

Moderate Interactions (Monitor Closely): - Corticosteroids: may enhance antiemetic effect, requiring dose adjustment. - Apomorphine: can potentiate hypotensive effects. - SSRIs, SNRIs, MAO inhibitors: monitor for signs of serotonin syndrome.